
    
      Patients will be treated with pemetrexed 500 mg/m2 IV and Bevacizumab 15 mg/kg IV every 3
      weeks.The patient is treated indefinitely until side effects are deemed severe by the
      investigator or until progression. Disease progression is measured every 6 weeks using RECIST
      criteria.
    
  